Related Experiment Video
Updated: Jun 18, 2026

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
Association Between Clonal Hematopoiesis and Cardiometabolic Disease: A Systematic Review and Meta-Analysis
Brooke D'Mello1, Neel Sheth2, Ani Orchanian-Cheff3
1Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Medicine, Temerty Faulty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Background:
Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cells. CH encompasses mosaic chromosomal alterations or somatic mutations in leukemia-driver genes (CH of indeterminate potential). Although CH has been associated with overall mortality, driven largely by cardiovascular disease, its links to individual cardiometabolic endpoints remain unclear.
Objectives:
The aims of this study were to systematically quantify the associations of CH with incident myocardial infarction, stroke, cardiovascular mortality, and type 2 diabetes and to assess whether these associations differ according to CH driver gene.
Methods:
MEDLINE, Embase, Cochrane, and CENTRAL were searched from inception through June 2025 for observational studies reporting age-adjusted associations between CH and cardiometabolic outcomes in adults. Animal and phenome-wide association studies were excluded. Using random-effects models, HRs were generated for primary outcomes. The risk for bias was assessed using the Newcastle-Ottawa Scale.
Results:
Eighteen studies encompassing more than 650,000 individuals were included, with 1 study of participants with hematological malignancy. CH was associated with increased incidence of myocardial infarction (HR: 1.14; 95% CI: 1.00-1.29), stroke (HR: 1.12; 95% CI: 1.03-1.23), cardiovascular mortality (HR: 1.20; 95% CI: 1.07-1.36), and type 2 diabetes (HR: 1.20; 95% CI: 1.02-1.41). In driver gene analyses, TET2 mutations were associated with a higher hazard of stroke (HR: 1.41; 95% CI: 1.03-1.93) and ASXL1 mutations with cardiovascular mortality (HR: 2.22; 95% CI: 1.37-3.60).
Conclusions:
CH is associated with cardiometabolic outcomes and may exhibit heterogeneity across mutations and clinical phenotypes, supporting its role as a somatic genomic marker of cardiometabolic risk. However, cautious interpretation and further study are required, as CH definitions were heterogeneous. (Association of Clonal Hematopoiesis with Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta Analysis; CRD420251156288).
Related Concept Videos
Hematopoiesis
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Regulation of Hematopoietic Stem Cells
Coronary Artery Disease I: Introduction
